Understand the source comparison
ARA-290 Stacking: Combination Comparison
ARA-290 + BPC-157 Anti-inflammatory priming + VEGF-driven angiogenesis ARA-290 every 48h; BPC-157 12-24h later, twice daily 40-60% faster tissue repair and wound closure vs monotherapy Both stable 28-60 days refrigerated; no premixing Gold standard for tissue
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290 + BPC-157
- Anti-inflammatory priming + VEGF-driven angiogenesis
- ARA-290 every 48h; BPC-157 12-24h later, twice daily
- 40-60% faster tissue repair and wound closure vs monotherapy
- Both stable 28-60 days refrigerated; no premixing
- Gold standard for tissue repair research. Mechanistic synergy is well-documented
- ARA-290 + TB-500
- Cytokine suppression + actin polymerization and cell migration
- ARA-290 every 48h; TB-500 24-48h later, twice weekly
- Enhanced fibroblast migration and collagen deposition; 35-50% improvement in tensile strength models
- TB-500 degrades 5-7% weekly; use fresh vials every 3-4 weeks
- Excellent for structural tissue research but requires strict cold chain adherence
- ARA-290 + Semax
- Neuroinflammation reduction + BDNF upregulation
- ARA-290 every 48-72h; Semax 300-600 mcg 2-3x daily starting 24h post-ARA-290
- Improved cognitive markers and synaptic plasticity; 25-40% increase in neurogenesis markers
- Semax stable 30-45 days; loses potency if left at room temp >2h before injection
- Top-tier neuroprotective stack; timing synchronization is critical for BDNF receptor sensitivity
- ARA-290 + Thymosin Alpha-1
- Inflammation control + adaptive immune priming
- ARA-290 every 48-72h; thymosin alpha-1 1.6 mg 48h later, every 3-4 days
- Reduced autoimmune disease severity scores by 40-50%; preserved pathogen defense
- Thymosin alpha-1 stable 60 days; tolerates 6-8h ambient temp
- Best choice for autoimmune research models; prevents cytokine storm while enhancing T-cell function
- ARA-290 + MOTS-c + SS-31
- Oxidative stress reduction + mitochondrial AMPK activation + cardiolipin stabilization
- ARA-290 every 48-72h; MOTS-c and SS-31 daily, 36h post-ARA-290
- 25-35% improvement in mitochondrial respiration and ATP production efficiency
- All three peptides stable 28-45 days; no known interaction precipitation
- Complex but potent metabolic stack; best for mitochondrial dysfunction research
- ARA-290 + Dihexa
- ROS suppression + HGF/c-Met agonism for neural growth
- ARA-290 every 48-72h; Dihexa 1-5 mg once daily, 36h post-ARA-290
- Amplified neurogenesis and dendritic spine density; 30-50% enhancement vs Dihexa alone
- Dihexa stable 30 days; degrades faster if exposed to light
- Potent cognitive stack but Dihexa's narrow therapeutic window requires precise dosing